Use the hyperlinks, where available to access additional clinical trial information.
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Eli Lilly and Company
Eligible participants will be randomly allocated to one of two arms. In Arm 1 (Experimental), participants will receive imlunestrant, administered orally. In Arm 2 (Active Comparator), participants will receive the Investigator's choice of tamoxifen, anastrozole, letrozole or exemestane, administered as per local approved label.